Steven Cohen Athenex, Inc. Transaction History

Point72 Asset Management, L.P.

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2020 Feb 16, 2021	SELL	$11.06 - $14.01 $2.99 Million - $3.79 Million	-270,636 Closed	0 $0
Q3 2020 Nov 16, 2020	SELL	$10.26 - $14.55 $104,272 - $147,871	-10,163 Reduced 3.62%	270,636 $3.28 Million
Q2 2020 Aug 14, 2020	SELL	$7.11 - $13.76 $638,485 - $1.24 Million	-89,801 Reduced 24.23%	280,799 $3.86 Million
Q1 2020 May 15, 2020	BUY	$5.71 - $15.85 $2.12 Million - $5.87 Million	370,600 New	370,600 $2.87 Million
Q4 2019 Feb 14, 2020	SELL	$9.6 - $17.75 $1.94 Million - $3.59 Million	-202,375 Closed	0 $0
Q3 2019 Nov 15, 2019	BUY	$12.16 - $21.0 $729,989 - $1.26 Million	60,032 Added 42.17%	202,375 $2.46 Million
Q2 2019 Aug 14, 2019	BUY	$9.44 - $19.8 $1.34 Million - $2.82 Million	142,343 New	142,343 $2.82 Million

1.46M

Ticker ATNX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 156,790,000
Market Cap $1.57M
Description
Athenex, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for the treatment of cancer. It operates through three segments: Oncology Innovation Platform, Global Supply Chain Platform, and Commercial Platform. The company's Orascovery product candidates include Oral paclitaxel and encequidar,...

Get notified when there are updates to the investment portfolio of Point72 Asset Management, L.P., based on Form 13F filings with the SEC.

Stay updated on Point72 Asset Management, L.P. and Steven Cohen with notifications on news.